Form D · Pharmaceuticals
Apnimed, Inc.
Cambridge, MA · CIK 0001745648
Offering snapshot reported Mar 27, 2026 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 11, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 27, 2026 | Initial | $24,999,994 | No comparison | 2 | SEC filing |
| Dec 8, 2025 | Amendment | $35,000,000 | $0vs Oct 1, 2025 | 7 | SEC filing |
| Oct 1, 2025 | Amendment | $35,000,000 | $12,000,000vs Sep 24, 2025 | 7 | SEC filing |
| Sep 24, 2025 | Initial | $23,000,000 | No comparison | 7 | SEC filing |
| Apr 24, 2025 | Initial | $16,499,982 | No comparison | 3 | SEC filing |
| Nov 8, 2023 | Initial | $0 | No comparison | 1 | SEC filing |
| Dec 23, 2022 | Initial | $79,749,950 | No comparison | 6 | SEC filing |
| Nov 1, 2022 | Amendment | $62,499,913 | $24,999,918vs May 10, 2022 | 14 | SEC filing |
| May 10, 2022 | Initial | $37,499,995 | No comparison | 14 | SEC filing |
| Apr 7, 2020 | Initial | $15,000,000 | No comparison | 1 | SEC filing |
| Aug 7, 2019 | Amendment | $25,575,714 | $6,000,000vs Jan 10, 2019 | 12 | SEC filing |
| Jan 10, 2019 | Amendment | $19,575,714 | $10,000,000vs Aug 9, 2018 | 12 | SEC filing |
| Aug 9, 2018 | Amendment | $9,575,714 | $4,500,001vs Jul 6, 2018 | 12 | SEC filing |
| Jul 6, 2018 | Initial | $5,075,713 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-578027
Source: Form D, filed Mar 27, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joseph C. Avellone | Director |
| Francois Beaubien | Director |
| Ramzi Benamar | Executive |
| Gerald Chan | Director |
| Isaac Cheng | Director |
| Chris C. Dimitropoulos | Director |
| Ron Farquhar | Director |
| Paul Fonteyne | Director |
| James Galeota | Director |
| Rosy Hu | Director |
| Ruoxi Hu | Director |
| Stefan Larson | Director |
| Kevin C. Lind | Director |
| Lawrence G. Miller | Director, Executive |
| Dennis Molnar | Executive |
| Michael Rogers | Executive |
| Gary Sender | Director |
| Barry Wohl | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
39 John F. Kennedy Street, 4 Th Flr.
Cambridge, MA, 02138
Phone: 877-276-4633
Cambridge, MA, 02138
Phone: 877-276-4633